These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17635822)

  • 1. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D; Donne RL; Hutchison AJ
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for hyperphosphatemia.
    Bellinghieri G; Santoro D; Savica V
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
    Cozzolino M; Brancaccio D
    Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanthanum carbonate.
    Freemont AJ
    Drugs Today (Barc); 2006 Dec; 42(12):759-70. PubMed ID: 17285149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanthanum carbonate: a new phosphate binder.
    Behets GJ; Verberckmoes SC; D'Haese PC; De Broe ME
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P; Barnett ME; Finn WF;
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of magnesium binders in chronic kidney disease.
    Spiegel DM
    Semin Dial; 2007; 20(4):333-6. PubMed ID: 17635824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
    Cozzolino M; Brancaccio D
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):341-3. PubMed ID: 17874964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorus management in end-stage renal disease.
    Finn WF
    Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F; Speake M; Hutchison AJ
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new era in phosphate binder therapy: what are the options?
    Salusky IB
    Kidney Int Suppl; 2006 Dec; (105):S10-5. PubMed ID: 17136110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
    Wilson R; Zhang P; Smyth M; Pratt R
    Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.